

NIH Materials CRADA

A valuable T2 mechanism for
obtaining unique research materials

Donna L. Bialozor, AACCP
Technology Transfer Center, NCI



Evolution of Materials CRADA

- Prior to MTA-CRADA NCI used MTA with “Invoke MTA” language
- PHS MTA-CRADA implemented May 30, 1996
- Current NIH Materials CRADA Model adopted April 19, 2006

Materials CRADA

- Materials CRADA is a hybrid of a CRADA and an MTA
- Research project defined and performed by the NIH investigator
- Used when company requires an upfront option to an exclusive license

Materials CRADA

- Company is providing an essential research material to the NIH
- Company's provision of proprietary material and any associated information is considered that party's collaborative contribution

Types of Materials NCI has received under Materials CRADA


- Proprietary Compounds/Small Molecules
- Hybridoma Cell lines
- Recombinant proteins
- Antibodies
- DNA Samples
- Transgenic Organisms
- Imaging Reagents
- Proprietary Device

MCRADA Vs. CRADA

- Level of NIH collaborative involvement with the non-Federal party
- Materials CRADA involves the transfer of proprietary material and related information to the NIH laboratory where no collaboration is intended

Active NCI CRADAS FY2005-FY2009

■ MCRADA ■ Standard ■ Total



	FY2005	FY2006	FY2007	FY2008	FY2009
MCRADA	59	56	60	71	80
Standard	99	91	96	100	99
Total	158	147	156	171	179

Acknowledgements

- Kathleen Carroll, Associate Director, TTC, NCI
- Karen Maurey, Director, TTC, NCI
- Tom Stackhouse, Associate Director, TTC, NCI